AR047841A1 - Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios - Google Patents
Metodos y composiciones para el tratamiento de transtornos inmunoinflamatoriosInfo
- Publication number
- AR047841A1 AR047841A1 ARP040103302A ARP040103302A AR047841A1 AR 047841 A1 AR047841 A1 AR 047841A1 AR P040103302 A ARP040103302 A AR P040103302A AR P040103302 A ARP040103302 A AR P040103302A AR 047841 A1 AR047841 A1 AR 047841A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- immune
- compositions
- methods
- inflammatory disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Método para el tratamiento de un paciente diagnosticado con un trastorno inmunoinflamatorio o con riesgo de desarrollar el mismo, que consiste en la administracion al paciente de una antihistamina, en combinacion con uno o más agentes adicionales. Composicion farmacéutica que contiene una antihistamina en combinacion con uno o más agentes adicionales.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50302603P | 2003-09-15 | 2003-09-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR047841A1 true AR047841A1 (es) | 2006-03-01 |
Family
ID=34375301
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040103302A AR047841A1 (es) | 2003-09-15 | 2004-09-15 | Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios |
Country Status (18)
Country | Link |
---|---|
US (1) | US20050192261A1 (es) |
EP (1) | EP1670427A4 (es) |
JP (1) | JP2007516217A (es) |
KR (1) | KR20060089725A (es) |
CN (1) | CN101102760A (es) |
AR (1) | AR047841A1 (es) |
AU (1) | AU2004273880A1 (es) |
BR (1) | BRPI0414435A (es) |
CA (1) | CA2537989A1 (es) |
IL (1) | IL174185A0 (es) |
IS (1) | IS8410A (es) |
MX (1) | MXPA06002929A (es) |
NO (1) | NO20061239L (es) |
RU (1) | RU2006112587A (es) |
SG (1) | SG146653A1 (es) |
TW (1) | TW200522932A (es) |
WO (1) | WO2005027839A2 (es) |
ZA (1) | ZA200601973B (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6765001B2 (en) * | 2001-12-21 | 2004-07-20 | Medicis Pharmaceutical Corporation | Compositions and methods for enhancing corticosteroid delivery |
GB2389530B (en) * | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
US7704527B2 (en) * | 2002-10-25 | 2010-04-27 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
TW200509958A (en) * | 2003-02-14 | 2005-03-16 | Combinatorx Inc | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
ZA200604253B (en) * | 2003-11-21 | 2007-10-31 | Combinatorx Inc | Methods and reagents for the treatment of inflammatory disorders |
US20070020330A1 (en) | 2004-11-24 | 2007-01-25 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
US8758816B2 (en) | 2004-11-24 | 2014-06-24 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
PT2377557T (pt) | 2004-11-24 | 2017-02-07 | Meda Pharmaceuticals Inc | Composições que compreendem azelastina e seus métodos de utilização |
JP4954085B2 (ja) | 2004-12-06 | 2012-06-13 | メディシノバ, インコーポレイテッド | 神経障害性疼痛及びその関連する症状を治療するためのイブジラスト |
PL1719507T3 (pl) | 2005-04-13 | 2010-12-31 | Cipher Pharmaceuticals Inc | Agoniści receptora beta2-adrenergicznego do leczenia chorób tkanki łącznej skóry |
EP1874821B1 (de) | 2005-04-26 | 2013-04-17 | Trion Pharma Gmbh | Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs |
EP1919450B1 (en) * | 2005-09-01 | 2014-06-11 | Meda AB | Antihistamine- and corticosteroid-containing liposome composition and its use for the manufacture of a medicament for treating rhinitis and related disorders |
US8067433B2 (en) * | 2005-11-09 | 2011-11-29 | Zalicus Inc. | Methods, compositions, and kits for the treatment of ophthalmic disorders |
US20070179121A1 (en) * | 2006-02-02 | 2007-08-02 | Plott R T | Method of treating pediatric patients with corticosteroids |
US20070225339A1 (en) * | 2006-03-07 | 2007-09-27 | Ramon Mohanlal | Compositions and methods for treating rheumatoid arthritis |
AU2007258567B2 (en) * | 2006-06-06 | 2012-04-19 | Medicinova, Inc. | Substituted pyrazolo (1,5-alpha) pyridine compounds and their methods of use |
US9205080B2 (en) | 2006-11-16 | 2015-12-08 | Transderm, Inc. | Methods of treating keratin hyperproliferation disorders using mTOR inhibitors |
GB0701171D0 (en) * | 2007-01-22 | 2007-02-28 | Imp Innovations Ltd | Compositions and uses thereof |
AR066016A1 (es) * | 2007-04-11 | 2009-07-15 | Alcon Res Ltd | Uso de un inhibidor del tnf alfa junto con una antihistamina para tratar la rinitis alergica y la conjuntivitis alergica |
US7536799B2 (en) * | 2007-06-07 | 2009-05-26 | Keson Industries | Chalk line apparatus with strategically located chalk fill opening |
AR066165A1 (es) * | 2007-09-18 | 2009-07-29 | Univ Stanford | Metodos de tratamiento de una infeccion viral de la familia flaviviridae, composiciones para el tratamiento de una infeccion viral de la familia flaviviridae y ensayos de control para identificar composiciones para el tratamiento de una infeccion viral de la familia flaviviridae |
US9101628B2 (en) * | 2007-09-18 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and composition of treating a flaviviridae family viral infection |
US9149463B2 (en) * | 2007-09-18 | 2015-10-06 | The Board Of Trustees Of The Leland Standford Junior University | Methods and compositions of treating a Flaviviridae family viral infection |
US8940730B2 (en) | 2007-09-18 | 2015-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions of treating a Flaviviridae family viral infection |
WO2010021681A2 (en) * | 2008-08-18 | 2010-02-25 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
WO2010048264A2 (en) * | 2008-10-23 | 2010-04-29 | Combinatorx, Incorporated | Methods and compositions for the treatment of immunoinflammatory disorders |
US8975247B2 (en) * | 2009-03-18 | 2015-03-10 | The Board Of Trustees Of The Leland Stanford Junion University | Methods and compositions of treating a flaviviridae family viral infection |
EA016240B1 (ru) * | 2009-10-13 | 2012-03-30 | Федеральное Государственное Учреждение "Государственный Научный Центр Дерматовенерологии Федерального Агентства По Высокотехнологичной Медицинской Помощи" | Способ прогнозирования эффективности лечения больных псориазом инфликсимабом |
GB201121812D0 (en) | 2011-12-07 | 2012-02-01 | Teva Branded Pharmaceutical Prod R & D Inc | NAsal formulation |
ES2506243T3 (es) * | 2012-09-05 | 2014-10-13 | Psoriasis+Creams Sweden Ab | Composición para tratar la psoriasis |
CN103830731A (zh) * | 2012-11-26 | 2014-06-04 | 天津金耀集团有限公司 | 糖皮质激素与h1受体拮抗剂的复方吸入组合物 |
CN103830208A (zh) * | 2012-11-26 | 2014-06-04 | 天津金耀集团有限公司 | 含有h1受体拮抗剂的吸入制剂 |
CN103830728A (zh) * | 2012-11-26 | 2014-06-04 | 天津金耀集团有限公司 | 环索奈德与h1受体拮抗剂的复方吸入药物 |
CN103830730A (zh) * | 2012-11-26 | 2014-06-04 | 天津金耀集团有限公司 | 布地奈德与h1受体拮抗剂的复方吸入药物 |
BR102012030828A2 (pt) | 2012-12-03 | 2014-09-16 | Ems Sa | Composição farmacêutica compreendendo desloratadina e prednisolona e seu uso |
US9370527B2 (en) | 2012-12-28 | 2016-06-21 | The Regents Of The University Of Michigan | Amelioration of intestinal fibrosis and treatment of Crohn's disease |
CA2899206C (en) | 2013-01-24 | 2019-07-09 | Transderm, Inc. | Compositions for transdermal delivery of mtor inhibitors |
EP3244916A4 (en) * | 2015-01-12 | 2018-06-27 | Agency For Science, Technology And Research | Monoclonal antibody against muramyl peptides in prevention and treatment of immune-mediated diseases |
CN104940179B (zh) * | 2015-05-29 | 2017-10-27 | 中国人民解放军第二军医大学 | 盐酸苯海拉明在制备治疗实验性自身免疫性脑脊髓炎药物中的应用 |
TWI830262B (zh) | 2015-06-30 | 2024-01-21 | 美商伊格集團國際股份有限公司 | 克立咪唑(clemizole)化合物於預防及治療肝癌之用途 |
RU2627424C1 (ru) * | 2016-11-03 | 2017-08-08 | Лонг Шенг Фарма Лимитед | Фармацевтический препарат для лечения ревматологических заболеваний |
JP7108631B2 (ja) | 2017-01-06 | 2022-07-28 | パルヴェラ セラピューティクス、インク. | mTOR阻害剤の無水組成物およびその使用方法 |
WO2019178516A1 (en) * | 2018-03-16 | 2019-09-19 | SEN-JAM Pharmaceutical LLC | Methods and compositions to treat enteropathic arthritis |
JP2021530463A (ja) | 2018-07-02 | 2021-11-11 | パルヴェラ セラピューティクス、インク. | mTOR阻害剤の無水組成物および使用方法 |
WO2022094422A1 (en) * | 2020-10-30 | 2022-05-05 | The Board Of Trustees Of The Leland Stanford Junior University | Drugs targeting inflammation for the treatment of osteoarthritis and other inflammatory diseases |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3231468A (en) * | 1962-07-02 | 1966-01-25 | Merck & Co Inc | Dexamethasone-cyproheptadine oral antiflammatory compositions |
US3419655A (en) * | 1967-03-17 | 1968-12-31 | American Home Prod | Treatment of inflammations by administering a cycloleucyl compound |
US4444780A (en) * | 1982-08-30 | 1984-04-24 | Ortho Pharmaceutical Corporation | Method for treating atopic dermatitis |
US5166149A (en) * | 1989-09-08 | 1992-11-24 | Chemex Pharmaceuticals, Inc. | Methotrexate compositions and methods of treatment using same |
US5030634A (en) * | 1990-03-29 | 1991-07-09 | Krumdieck Carlos L | 10-deazaaminopterin: a new arthritis remittive drug |
CZ293873B6 (cs) * | 1994-10-05 | 2004-08-18 | Loderácari | Léčivo pro léčbu sclerosis multiplex nebo jiných demyelinizačních stavů |
AU4472396A (en) * | 1994-12-30 | 1996-07-24 | American Home Products Corporation | Clear non-alcoholic hydrocortisone solutions |
US5736537A (en) * | 1995-09-12 | 1998-04-07 | Estee Lauder, Inc. | Dehydroep:androsterone sailcylate useful against skin atrophy |
EP0780127A1 (en) * | 1995-12-19 | 1997-06-25 | The Procter & Gamble Company | A nasal spray containing a steroid and a antihistamine |
BR9709650A (pt) * | 1996-06-04 | 1999-08-10 | Procter & Gamble | Aerosol nasal contendo um esteróide intransal e um anti-histamínico |
IN188720B (es) * | 1997-11-06 | 2002-11-02 | Panacea Biotec Ltd | |
US6140337A (en) * | 1997-12-23 | 2000-10-31 | Schering Corporation | Methods for the treatment of mental disorders |
US6423721B1 (en) * | 1998-09-10 | 2002-07-23 | Schering Corporation | Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines |
WO2000035454A1 (en) * | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
EP1049471A1 (en) * | 1999-03-01 | 2000-11-08 | Schering Corporation | Compositions and methods for treating atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoids |
GB0023220D0 (en) * | 2000-09-21 | 2000-11-01 | Arakis Ltd | Corticosteroid formulation |
US20020006961A1 (en) * | 1999-05-14 | 2002-01-17 | Katz Stanley E. | Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response |
US20020061281A1 (en) * | 1999-07-06 | 2002-05-23 | Osbakken Robert S. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
WO2001026658A2 (en) * | 1999-10-08 | 2001-04-19 | Schering Corporation | Topical nasal treatment using desloratadine |
EP1267870A2 (en) * | 2000-04-07 | 2003-01-02 | Schering Corporation | Inhibition of cytokine generation |
US6488937B1 (en) * | 2000-08-23 | 2002-12-03 | William Smits | Allergy treatment method using a rapid immunotherapy protocol |
ATE469907T1 (de) * | 2000-10-02 | 2010-06-15 | Univ Emory | Triptolid-analoga zur behandlung von autoimmunkranheiten und entzündungen |
US6599914B2 (en) * | 2001-04-24 | 2003-07-29 | Schering Corporation | Inhibition of cytokine generation |
US7034059B2 (en) * | 2001-07-02 | 2006-04-25 | Sepracor Inc. | Methods of using norfluoxetine |
WO2003020274A1 (en) * | 2001-08-30 | 2003-03-13 | Aventis Pharmaceuticals Inc. | Treatment of atopic dermatitis |
US20040220153A1 (en) * | 2002-09-24 | 2004-11-04 | Jost-Price Edward Roydon | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
TW200509958A (en) * | 2003-02-14 | 2005-03-16 | Combinatorx Inc | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
-
2004
- 2004-09-14 US US10/940,902 patent/US20050192261A1/en not_active Abandoned
- 2004-09-14 TW TW093127736A patent/TW200522932A/zh unknown
- 2004-09-15 CN CNA2004800336483A patent/CN101102760A/zh active Pending
- 2004-09-15 BR BRPI0414435-0A patent/BRPI0414435A/pt not_active IP Right Cessation
- 2004-09-15 EP EP04784162A patent/EP1670427A4/en not_active Withdrawn
- 2004-09-15 MX MXPA06002929A patent/MXPA06002929A/es unknown
- 2004-09-15 ZA ZA200601973A patent/ZA200601973B/xx unknown
- 2004-09-15 WO PCT/US2004/030210 patent/WO2005027839A2/en active Application Filing
- 2004-09-15 AU AU2004273880A patent/AU2004273880A1/en not_active Abandoned
- 2004-09-15 SG SG200806907-2A patent/SG146653A1/en unknown
- 2004-09-15 JP JP2006526998A patent/JP2007516217A/ja active Pending
- 2004-09-15 RU RU2006112587/15A patent/RU2006112587A/ru not_active Application Discontinuation
- 2004-09-15 AR ARP040103302A patent/AR047841A1/es unknown
- 2004-09-15 CA CA002537989A patent/CA2537989A1/en not_active Abandoned
- 2004-09-15 KR KR1020067006026A patent/KR20060089725A/ko not_active Application Discontinuation
-
2006
- 2006-03-08 IL IL174185A patent/IL174185A0/en unknown
- 2006-03-17 NO NO20061239A patent/NO20061239L/no not_active Application Discontinuation
- 2006-04-12 IS IS8410A patent/IS8410A/is unknown
Also Published As
Publication number | Publication date |
---|---|
IL174185A0 (en) | 2006-08-01 |
TW200522932A (en) | 2005-07-16 |
EP1670427A2 (en) | 2006-06-21 |
CA2537989A1 (en) | 2005-03-31 |
MXPA06002929A (es) | 2006-06-14 |
US20050192261A1 (en) | 2005-09-01 |
BRPI0414435A (pt) | 2006-11-14 |
RU2006112587A (ru) | 2007-10-27 |
KR20060089725A (ko) | 2006-08-09 |
EP1670427A4 (en) | 2009-01-07 |
SG146653A1 (en) | 2008-10-30 |
AU2004273880A1 (en) | 2005-03-31 |
WO2005027839A3 (en) | 2007-06-28 |
IS8410A (is) | 2006-04-12 |
NO20061239L (no) | 2006-06-08 |
ZA200601973B (en) | 2008-08-27 |
CN101102760A (zh) | 2008-01-09 |
JP2007516217A (ja) | 2007-06-21 |
WO2005027839A2 (en) | 2005-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR047841A1 (es) | Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios | |
CY1120384T1 (el) | Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων | |
NO20170633A1 (no) | Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff . | |
CY1111458T1 (el) | Μορφες δοσολογιας γενικως γραμμικης, αναβραζουσας, απο του στοματος φεντανυλης και μεθοδοι χορηγησης | |
AR060306A1 (es) | Terapia de combinacion de anticuerpos contra ctla4 | |
AR058182A1 (es) | Metodos, composiciones y equipos par el tratamiento de afecciones medicas | |
BRPI0415397A (pt) | métodos e reagentes para o tratamento de desordens imunoinflamatórias | |
AR043188A1 (es) | Metodos y composiciones para el tratamiento de enfermedades y trastornos asociados con niveles elevados de citoquinas proinflamatorias | |
UY27940A1 (es) | Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a | |
EA202091999A2 (ru) | Применение ингибиторов dpp iv | |
CY1118179T1 (el) | Φαρμακευτικη συνθεση | |
DE602005010788D1 (de) | Pharmazeutische Zusammensetzungen zur sicheren Verabreichung von bei der Behandlung von Drogenabhängigkeit verwendeten Arzneimitteln | |
CY1112738T1 (el) | Μια συνδυασμενη συνθεση που περιεχει ιβουπροφαινη και παρακεταμολη | |
CY1112387T1 (el) | Θεραπευτικη συνθεση περιεχουσα τουλαχιστον ενα παραγωγο της πυρρολοβενζοδιαζεπινης και φλουδαραβινη | |
ECSP066365A (es) | Anilino purinas sustituidas en la posición 6 útiles como inhibidores de rtk | |
NO20050807L (no) | Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser | |
ECSP077401A (es) | Medicamentos que contienen compuestos de carbonilo y su uso | |
CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
ECSP088440A (es) | Imidazopirazinas como inhibidores de proteinquinasa | |
AR033175A1 (es) | Usos farmaceuticos de bisfosfonatos | |
TW200600087A (en) | Methods and compositions for treating amyloid-related diseases | |
MXPA05014166A (es) | Metodos y composiciones para tratar enfermedades relacionadas con amiloide. | |
AR053928A1 (es) | Metodos reactivos para el tratamiento de trastornos inflamatorios | |
EA200501821A1 (ru) | Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат | |
BR0313413A (pt) | Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |